News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DBV Technologies Enters Into Collaboration Agreement With Bionet-Asia And University of Geneva On Whooping Cough Booster Vaccine


11/26/2013 10:02:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PARIS, BANGKOK, Thailand and GENEVA, Nov. 26, 2013 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext Paris:DBV), creator of Viaskin®, announced today that it has entered into a collaboration agreement with BioNet-Asia Co. Ltd and the University of Geneva (UNIGE) to work on a whooping cough (pertussis) booster vaccine. The clinical proof of concept product candidate will combine BioNet's unique recombinant non-toxic Pertussis Toxin (rPT) with DBV's Viaskin® technology, which allows for the epicutaneous delivery of the antigen without any adjuvant.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES